Paclitaxel plus carboplatin

DRUG5 trials

Conditions

ChemoradiotherapyEsophageal Squamous Cell CarcinomaMelanoma, Cutaneous MalignantNeoplasmsPulmonary Large Cell Neuroendocrine CarcinomaSurvivalTriple Negative Breast Cancer

Phase 1

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

CompletedNCT02723955

GlaxoSmithKlineNeoplasms

Start: 2016-06-23End: 2023-07-05Updated: 2024-12-27

Phase 2

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

NCT01276769

Chinese Academy of Medical SciencesTriple Negative Breast Cancer

Start: 2008-01-31End: 2012-07-31Target: 80Updated: 2011-11-16

Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma

NCT02943798

Shanghai Chest HospitalPulmonary Large Cell Neuroendocrine Carcinoma

Start: 2016-12-31End: 2018-12-31Target: 118Updated: 2016-10-25

Phase 3

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

RecruitingNCT06743126

Immatics US, Inc.Melanoma, Cutaneous Malignant

Start: 2025-01-14End: 2031-10-01Target: 360Updated: 2026-03-19

Unknown Phase

Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)

RecruitingNCT04519905

Fudan UniversityChemoradiotherapy, Esophageal Squamous Cell Carcinoma, Survival

Start: 2020-01-06End: 2027-12-31Target: 320Updated: 2021-11-02

Journal of Clinical Oncology2025-05-28

SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator’s choice in patients with previously treated advanced cutaneous melanoma.

Journal of Clinical Oncology2025-05-28

INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.

2024-02-1310 citations

Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade

Cancer Research Communications2023-07-1914 citations

Abstract CT033: Inducible T cell costimulatory (ICOS) receptor agonist, feladilimab (FE), alone and in combination (combo) with pembrolizumab (PE): Results from INDUCE-1 relapsed/refractory (R/R) melanoma expansion cohorts (EC)

Cancer Research2021-07-011 citations

Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs).

Journal of Clinical Oncology2021-05-2031 citations

Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology2020-05-2017 citations

INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors.

Journal of Clinical Oncology2020-05-2010 citations

First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1

Annals of Oncology2018-10-0111 citations

Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors

Cancer Research2017-07-017 citations

INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.

Journal of Clinical Oncology2017-05-2011 citations

Abstract IA22: Targeting inducible T cell co-stimulator (ICOS) promotes effector T cell function and antitumor response

Cancer Immunology Research2016-10-31

Abstract P3-14-07: Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer - A phase II clinical trial

Cancer Research2013-12-158 citations